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Background: The United States has the highest rate of incarceration in the world (937 per 100,000 adults).
Approximately one-third of heroin users pass through correctional facilities annually. Few receive medication
assisted treatment (MAT; either methadone or buprenorphine) for opioid use disorder during incarceration, and
nearly three-quarters relapse to heroin use within 3 months of release. This qualitative study investigated barriers
to and facilitators of buprenorphine maintenance treatment (BMT) following release from incarceration (“re-entry”).
Methods: We conducted 21 semistructured interviews of former inmates with opioid use disorder recruited from
addiction treatment settings. Interviews were audio-recorded, transcribed, and analyzed using a grounded theory
approach. Themes that emerged upon iterative readings of transcripts were discussed by the research team.
Results: Participants reported adverse re-entry conditions, including persistent exposure to drug use and stressful
life events, which were perceived to contribute to opioid relapse and affected addiction treatment decisions during
re-entry. Themes that emerged relating to BMT included: 1) reliance on willpower; 2) fear of dependency on medications;
3) variable exposure to buprenorphine; and 4) acceptability of BMT following relapse. Willpower was perceived to be
more important for recovery than medications. Many participants experienced painful withdrawal from methadone
during incarceration and were fearful that using MAT would lead to opioid tolerance and painful withdrawal again in
the future. Participants reported both positive and negative experiences taking illicit buprenorphine, which affected
interest in BMT. Overall, BMT was perceived to be a good treatment option for opioid use disorder that could reduce
the risk of re-incarceration.
Conclusions: BMT was perceived to be acceptable, but former inmates with opioid use disorder may be reluctant to
utilize BMT upon re-entry. Factors limiting utilization of BMT could be mitigated though policy change or interventions.
Policies of the criminal justice system (e.g., forced detoxification) may be dissuading former inmates from utilizing
effective treatments for opioid use disorder. Interventions that improve education and access to BMT for former
inmates with opioid use disorder could facilitate entrance into treatment. Both policy changes and interventions
are urgently needed to reduce the negative consequences of opioid relapse following re-entry.
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The United States has the highest rate of incarceration in
the world (937 per 100,000 adults). At the end of 2011,
7 million Americans were under correctional supervision,
including 2.2 million held in jail or prison [1]. Of those in-
carcerated, nearly two-thirds (1.5 million) have substance
use disorders, including up to one-quarter with opioid use
disorder [2-4]. It has been estimated that one-third of her-
oin users pass through correctional facilities annually [5].
Few inmates with opioid use disorder receive addiction
treatment during incarceration, and rates of relapse and
opioid overdose-related deaths (109 deaths per 100,000
person years, or 15 percent of all deaths among former
inmates) are tragically high following release [6-9].
Medication assisted treatment (MAT), using methadone
or buprenorphine, are the most effective treatments for
opioid use disorder, with decades of research demonstrat-
ing reductions in opioid abuse, HIV risk behaviors, and
criminal recidivism [10,11]. However, of the 28 state prison
systems that offer any methadone treatment, over half limit
treatment to pregnant women or individuals with chronic
pain, and only seven state prison systems offer any bupre-
norphine treatment [12-14]. Consequently, for some,
opioid abuse continues during incarceration [15,16].
Even when inmates maintain abstinence from opioids
during incarceration, because opioid use disorder is a
chronic relapsing illness, they are at high risk for opioid
relapse following release [17,18]. Randomized controlled
trials and observational studies have demonstrated that
starting methadone or buprenorphine prior to release
improves entrance into and retention within addiction-
treatment and reduces opioid abuse following release
[7,19-23], but data regarding the impact of pre-release
MAT on recidivism has been conflicting [24,25]. None-
theless, these practices have not become standard of care.
Relapse to opioid use following release from incarceration
(“re-entry”) is extremely common, which makes the period
of community re-entry following release critical to engage
former inmates with opioid use disorder in treatment.
Nearly three-quarters of prisoners with opioid use disorder
relapse within 3 month of release, and with simple referral
to MAT upon release, as few as 8 percent enter treatment
[21]. Qualitative research focused on community re-entry
has highlighted factors that contribute to relapse, including
poor social support, inadequate economic resources, and
widespread exposure to drug use, but barriers to addiction
treatment were not investigated [26,27]. Barriers to medical
care during re-entry include competing priorities, lack of
knowledge about services, long waiting times, and costs of
treatment, but there may be additional factors specific to
addiction treatment and MAT that prevent former inmates
from entering treatment [28]. Understanding how the
experience of community re-entry affects former in-
mates’ attitudes toward and access to MAT could aidin development of interventions that encourage treatment,
thereby preventing relapse, overdose, and re-incarceration.
Buprenorphine maintenance treatment (BMT) is an in-
creasingly utilized, efficacious, and safe treatment for opioid
use disorder, and it has several features that may enhance
acceptability [29-33]. Private physicians in office-based
settings can prescribe BMT, which may reduce stigma;
side effects may be more tolerable than methadone; and pa-
tients may self-administer BMT, as opposed to methadone
maintenance treatment (MMT) programs, where nurses
administer and directly observe most dosing [34-36].
Qualitative data suggest that former inmates may prefer
BMT to MMT [36]. Therefore, BMT has promise for re-
ducing the consequences of opioid relapse during commu-
nity re-entry, but it has yet to be fully realized.
To better understand why former inmates would or
would not initiate MAT in general, and BMT more spe-
cifically, we conducted a qualitative study of the barriers
to and facilitators of BMT following re-entry. Findings
from this study will inform an intervention to facilitate
entrance into BMT following re-entry and can be used
to develop policy regarding MAT and incarceration.
Methods
We conducted semistructured interviews with 21 former
inmates with opioid use disorder between November 2012
and December 2013. The study was approved by the Insti-
tutional Review Board of the Albert Einstein College of
Medicine.
Participants
Inclusion criteria were: 1) incarceration (≥1 day in jail or
prison) in the previous 5 years; 2) opioid use disorder; 3)
18 years of age or older; and 4) fluent in English or
Spanish. Sampling was by convenience, but we targeted
recruitment to include participants with variability re-
garding experiences taking buprenorphine (BMT, illicit
buprenorphine only, and no buprenorphine) and length
of time since re-entry. Primary care providers at a federally
qualified health center (FQHC) that houses an office-based
BMT program [37] and a re-entry program for former
inmates [38] referred patients who met inclusion criteria.
Drug counselors at an outpatient substance abuse treat-
ment program that provides nonpharmacologic addiction
treatment to former inmates (often as part of parole
requirements) also referred clients to study. This ensured
inclusion of those who sought addiction treatment by
choice and those who were mandated to treatment.
Interviews
After obtaining informed consent, face-to-face interviews
lasting approximately one hour were conducted in a pri-
vate room at the FQHC or substance abuse treatment pro-
gram. All interviews were audio-taped and professionally
Table 1 Sociodemographic characteristics of former
inmates with opioid use disorder
Characteristic N (%)




Non-Hispanic Black 8 (38)
English-speaking 20 (95)
Medicaid 19 (90)
High school diploma or equivalency 11 (52)
Ever injected drugs 15 (71)
Current substance usea
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and participants were compensated with $20 and a $5
transit pass. An interview guide was developed to elicit
participants’ experiences with opioid use disorder, incar-
ceration, and community re-entry; attitudes toward MAT;
and beliefs about buprenorphine. Interview questions were
based on Social Cognitive Theory (SCT), which models a
pathway of behavior change that has frequently been
applied to addiction [39]. According to SCT, self-efficacy,
outcome expectations, goals, and structural barriers/
facilitators are all important domains relating to behavior
change; therefore, interview questions addressed these do-
mains in relation to why or why not participants engaged
in MAT in general, and BMT more specifically, during
community re-entry.Heroin 6 (29)








Nonpharmacologic treatment 20 (95)
BMT 8 (38)
Any opioid addiction treatment 21 (100)
aWithin the previous 30 days.
bRegular use within lifetime.Analysis
We analyzed the data in an iterative process using a
Grounded Theory approach. Three investigators (ADF,
JM, JS) developed a coding scheme to categorize com-
mon themes that emerged upon iterative readings of the
first five transcripts. Several codes overlapped with do-
mains of SCT (e.g., goals for addiction treatment follow-
ing release), and others related to common experiences
(e.g., returning to housing that exposed participants to
substance use). This coding list was then applied to all
21 transcripts with two investigators independently cod-
ing each one. Transcripts were then discussed by the en-
tire research team, and discrepancies in coding or
revisions to the coding list were resolved by consensus.
Agreed-upon codes were entered into N-Vivo software,
so that content from all transcripts could be sorted and
extracted by code. The research team then retrieved and
discussed content from all transcripts by code to further
understand and refine the common themes.Results
Participants were mostly male, Hispanic or African
American, English-speaking, and the median age was 49
(see Table 1). They had used heroin for a median of
24 years (interquartile range [IQR]: 15–30) in their life-
times, and six reported using heroin in the previous
30 days. Nearly all had a history of injection drug use,
MMT, and had received abstinence-based addiction treat-
ment during incarceration. They had been incarcerated
for a median of 16 years (IQR: 5.5–26) as adults, and re-
lease from prison or jail was a median of 7.5 months
(range: 10 days–4 years) prior to the interview. Overall, 12
participants had taken buprenorphine, including eight
who had ever received BMT, six who received BMT at the
time of the interview, and four who had tried illicit bupre-
norphine but had never received BMT. Experience with
relapse varied, with more than two-thirds relapsing toopioid use during community re-entry, and only half of
these participants starting MAT.
During community re-entry, most participants experi-
enced adverse re-entry conditions, which included struc-
tural or psychosocial challenges that affected decisions
about addiction treatment, and often which led to opioid
relapse. Participants’ experiences regarding post-release
opioid addiction treatment varied greatly, with a few start-
ing BMT immediately following release and others refus-
ing any type of MAT. Decisions regarding MAT in general
and BMT specifically fell within four broad themes: 1) reli-
ance on willpower; 2) fear of dependency on medications;
3) variable exposure to buprenorphine; and 4) acceptabil-
ity of BMT following relapse. Below, we describe the
adverse re-entry conditions and then elaborate on each
of these themes, including how they were barriers to or
facilitators of BMT.
Adverse re-entry conditions
Decisions regarding addiction treatment during commu-
nity re-entry were made within the context of stressful life
events and living conditions that made long-term abstin-
ence difficult. Both structural factors, like exposure to drug
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such as isolation and hopelessness, were accentuated
during re-entry and were perceived to contribute to re-
lapse. A participant who relapsed to heroin use during
re-entry and subsequently started BMT described his
housing conditions:
I lived in the halfway house…and a lot of people get
high, people selling drugs, you go in the bathroom and
find empty heroin bags, people leave their works in
there. (Participant 1)
Other participants described the stress of living with
family members and needing to contribute to rent, despite
not having employment or a source of income. Addition-
ally, relationships with family members were often strained
by the participant’s history of addiction and repairing these
relationships was stressful. One participant described the
impact of substance use and incarceration on her family:
The reason why I couldn’t stop [using drugs] is because
you lose your custody of your kids, your family, they
don’t trust you and you’re just like an outcast, and
they’re waiting and expecting you to just relapse and it
hurts you. It hurts you emotionally. (13)
Participants also commonly described the material things
or relationships that they had lost due to incarceration and
how difficult it was to start over during community re-
entry; this often led to hopelessness. One participant
who had maintained abstinence following his most re-
cent incarceration reflected on the challenges of finding
meaning in post-incarceration life and avoiding relapse:
Could you imagine – a person comes home and they
have nothing. They’ve lost their family. They have no
prospects for a job. They have almost literally nothing
to live for. What is going to stop that person from saying
well, let me just get high? I have nothing else. (5)
A few participants reported having a positive social sup-
port system, including spouses or re-entry programs, but
more commonly, participants were socially isolated and
unprepared for the challenges of community re-entry.
The following themes contributed to decisions about
MAT in general, and BMT more specifically:
Reliance on willpower
Participants expressed that not using opioids was a per-
sonal decision and emphasized that individual traits like
willpower and readiness to change were more important
than participation in addiction treatment. This reliance on
willpower could be a barrier to MAT; it also led to internal
conflict if participants relapsed. Nearly all participantscommented that accepting personal responsibility for
addiction was an essential first step in not using opioids.
One participant who was abstinent at the time of the
interview explained why he chose not to start BMT during
re-entry:
Programs, doctors, drugs, whatever, they could only do
so much. The person has to bear some kind of
responsibility in this whole equation. I have to take
responsibility for my own life. (5)
Another participant who was offered BMT by his phys-
ician during community re-entry, but had refused BMT,
also emphasized personal responsibility:
The first things is the desire to overcome [addiction]. If
you want to overcome it, that’s number one. If you’re not
interested, you’re not going to go anywhere. No matter
how much they try to help you, they can’t go inside your
head and obligate you. It has to be you. (11)
However, accepting personal responsibility for addiction
seemed to be necessary but not sufficient to prevent re-
lapse. Participants described prior episodes of community
re-entry in which they had felt ready to stop using opioids,
yet still experienced relapse. One participant recognized
that he had been in similar situations previously and had
relapsed:
Sometimes I thought – I tried to deceive myself. This
time I’m going to do things right. I didn’t last a month
before I was back selling and using drugs. (11)
Another participant who had felt ready to stop using
opioids at release, but still relapsed to heroin use, described
the internal conflict. Following relapse, this participant
started BMT and was able to maintain abstinence, but he
reflected on his struggles when relying on willpower alone:
Maybe I just didn’t have no willpower, and just had to
use. But I really didn’t. I was really trying to contemplate
a scenario where I wouldn’t be using heroin. You know
what I’m saying? And it didn’t work out like that, you
know. (1)
Regardless of past experiences with relapse, many par-
ticipants still believed that if they had sufficient will-
power, they would be able to stop using opioids. Reasons
for wanting to stop included parental responsibilities,
failing health, fear of going back to prison, or simply
“being tired”. Overall, there was a sense of confidence
at the time of the interviews that they would be able to
stop using opioids, even among participants who had
already relapsed since re-entry. One participant who had
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interview, but who was not interested in starting BMT,
reported:
I think drugs have outran their course in me…they have
really made me see the error of me, though. At times, I
rely on the high to not feel something that I’m going
through at that particular moment. But, I’ve grown to
understand that whatever I go through and if I’m
[thinking] a drug is going to erase it, it’s not. (19)
Fear of dependency
When participants did receive addiction treatment, there
was often a preference for medication-free approaches due
to the fear of becoming dependent on opioids. Though a
few participants started BMT or MMT immediately
following release, for most participants, their goal was
to be free of opioids (“clean”), which included medications.
There were two main reasons for the medication-free
preference: dependence on medications was perceived as a
step backward in recovery, and it was a setup for painful
withdrawal in the future.
A step backward Though a few participants managed
to use enough illicit opioids during incarceration to maintain
opioid tolerance (or “a habit”) for the most part, participants
drastically reduced their opioid use while incarcerated and
perceived themselves to be “clean” at release. A participant
who had experience with both MMT and BMT described
how using MATat release was counter-intuitive for him:
I’ve been incarcerated for 8 years…as soon as I’m going
home I’m going to a methadone program? Why do you
need to go to a methadone program when you’ve been
8 years clean? (6)
Another participant who later entered MMT commen-
ted on his mentality at release, “I don’t have no drugs in
me. I don’t need [buprenorphine]…I’m clean”. (20) For this
participant, and others who utilized MAT, the dependency
on medication seemed like a failure, because they still
maintained a goal of being opioid-free. This participant
spoke about “trading one drug for another” and the psy-
chological effect of MAT, “Right now I’m in the methadone
program. I know that’s legal and everything, but I don’t feel
clean. The same thing for [buprenorphine]”. (20)
Setup for withdrawal Participants’ experiences with
withdrawal from methadone while incarcerated also con-
tributed to the fear of dependency. For participants who
were receiving MMT when they were incarcerated, all
were involuntarily and rapidly detoxified from methadone
and experienced prolonged withdrawal symptoms. The
withdrawal symptoms were severe, persisted for months,and traumatized participants. One participant described
the severity of the withdrawal symptoms:
Since I was in the meth program, they detoxed me and
it was really cruel. I was going crazy. I wanted to hang
myself and I couldn’t deal with it. Honestly, when I
finished, I was in so much pain that I had to go to the
psychiatrist so I could try to get some type of pill. (16)
The trauma of these experiences often resulted in an
aversion to methadone that could eliminate MMTas an ac-
ceptable treatment option, “I would never take methadone
again. Hell, no. I suffer[ed]”. (6) The aversion to methadone
did not seem to convey negative attitudes toward buprenor-
phine, and for a few participants, the painful withdrawal
during incarceration led them to try BMT as an alternative.
There were no participants who were receiving BMT at the
time of incarceration, so any aversion to BMT was due to
prior adverse reactions to buprenorphine, not because of
their experience with withdrawal from buprenorphine.
Variable exposure to buprenorphine
During incarceration, BMT was not prescribed and was
not part of participants’ addiction education; however, most
had either taken or heard about illicit buprenorphine
before or during incarceration. This haphazard exposure
to buprenorphine made participants’ experiences variable,
which affected attitudes toward BMT. Several participants
reported negative experiences taking buprenorphine, but
this was in the context of illicit buprenorphine use, with-
out the supervision of a physician. One participant who
had relapsed to opioid use following release, but who was
not interested in BMT, reported a prior negative experi-
ence taking illicit buprenorphine:
The dude just gave [buprenorphine] to me and didn’t
tell me I had to be careful and I took the whole thing.
All of a sudden I lost control of everything. My bowel
movement, my urine, everything. My equilibrium was
totally thrown off track. And when I got home I fell out
and woke up in the hospital. (14)
Alternatively, when illicit buprenorphine was used effect-
ively to self-treat withdrawal symptoms during incarcer-
ation or when BMT was provided by a physician during
re-entry, participants reported more positive attitudes to-
ward BMT. One participant had taken illicit buprenorphine
during a short jail stay to self-treat withdrawal symptoms
and then started BMT during re-entry:
That’s how I found out about the [buprenorphine] in
jail…I got so sick in there — sweating, nightmares, you
couldn’t even go to sleep right…I mean I never ever
heard about [buprenorphine] and [another inmate]
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they calmed me down. (2)
Acceptability of BMT following relapse
Despite the reliance on willpower and fear of dependency,
for the majority of participants, BMT was perceived as a
good way to prevent re-incarceration and commonly was
seen as a better option than MMT. In response to ques-
tions about the ideal treatment approach to prevent relapse
during re-entry, participants recommended more wide-
spread use of BMT through improved education, access to
physicians, or specific programs that could be implemented
within correctional facilities. One participant who had re-
lapsed during re-entry and then started BMT believed that
BMT should routinely be offered during incarceration:
The average person, they would be discharged from
jail or prison, [they’re] scared okay. And 95 percent of
the time drugs [are] what got them in prison or jail.
And, a lot of them don’t want to go back to that. But if
you had like these pre-release programs and let them
know you have an alternative, you don’t have to go on
the methadone program, you can have [buprenorphine]
and then follow suit so that you won’t get locked up. (9)
Even among participants who had never tried bupre-
norphine, there was recognition that BMT could prevent
re-incarceration and would be a viable option if they
needed it. Several participants had spouses or family mem-
bers who received BMT. One participant who chose not
to receive MAT still had a positive impression of BMT:
I heard that it stops the craving. I see my brother stable
now. He’s not going out there searching for a bag of dope or
trying to sell something. He’s calm. He’s got a good job. (12)
Overall, BMT was perceived to be acceptable, but often
participants chose to wait to enter treatment until they had
a “dirty urine” (i.e., following relapse to opioid use). One
participant who had previously received BMT but elected
for medication-free treatment following his most recent re-
entry described BMT as an acceptable “Plan B” (8) if group
treatment did not work for him. For other participants, it
took relapse before they sought treatment, but ultimately,
they were able to access BMT and they acknowledged that
the medication helped them avoid re-incarceration:
Soon after I started back using [drugs], these two kids
in the halfway house told me about [buprenorphine]. I
already had a doctor so I asked him about it and we
discussed it. And I was concerned about being on
parole and taking [buprenorphine], and he was like,
“Trust me. Your parole officer would prefer you to be
on [buprenorphine] than heroin”. [Now], I don’t havecravings for heroin, and if I had cravings for heroin, I’d
be back into using heroin again. And that would, you
know, automatically turn back to a life of crime. And
that will definitely get you back to prison. (1)
Discussion
In this qualitative study on perceptions of opioid addiction
treatment during community re-entry, participants univer-
sally reported adverse re-entry conditions, and we identi-
fied several important themes relating to decisions about
BMT. Reliance on willpower and fear of dependency often
led participants to favor medication-free treatment. How-
ever, following relapse, BMT was seen as an acceptable
treatment option that had the potential to prevent re-
incarceration, especially among participants who had
positive experiences or impressions of buprenorphine.
Our study expands the literature on post-incarceration
relapse to substance use by offering insights into why
former inmates may not seek MAT. Two other recent
qualitative studies described the re-entry experiences of
substance users and have similarly documented the adverse
re-entry conditions, including exposure to drug use and
ubiquitous psychosocial distress [26,27]. Several studies
have also demonstrated gaps in knowledge about BMT
among more general populations of opioid users [40-42].
Our study builds upon these studies by demonstrating
how attitudinal barriers, such as fear of dependency
and the potential over-reliance on willpower, may also
affect decisions about BMT during community re-entry.
While correctional systems or courts often favor abstinence-
based approaches to opioid addiction treatment [12], our
participants’ preference for medication-free approaches to
treatment was surprising. This emerging literature is far
from complete, and a better understanding of treatment
seeking and treatment fears will be critical for designing
policy and interventions to reduce relapse during com-
munity re-entry.
Our findings reiterate that opioid use disorder is a
chronic disease that is not cured by the forced abstinence
of incarceration. Our participants desired to be opioid-free
but were unprepared to face the adverse re-entry condi-
tions. During re-entry, most relapsed and either started
MAT or continued to use opioids. It is possible that some
participants will achieve sustained abstinence, but it is un-
likely that reliance on willpower alone will be sufficient for
most. Our study highlights the need for additional opioid
addiction treatment options, including MAT and longitu-
dinal aftercare, for most former inmates with opioid use
disorder during community re-entry. With the high rate
of opioid overdose death immediately following release [8]
and the data demonstrating that pre-release MAT in-
creases utilization of addiction treatment during re-entry
[7,19-23], we question the wisdom of releasing inmates
who have long histories of opioid use disorder without at
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will be reluctant to start MAT, with better education
and linkage to treatment, others would find BMT ac-
ceptable, and starting treatment could avert relapse and
overdose-related deaths.
One theme, the fear of dependency, is of particular
interest because it could limit utilization of effective treat-
ments. The stigma of MAT or “trading one addiction for
another” is well known [43], but correctional policies that
require rapid detoxification from MAT may also be ex-
acerbating this fear of dependency. After repeated incar-
cerations, opioid users’ reluctance to receive MAT may
reflect an acceptance that future incarceration is probable,
as well as their desire to avoid the painful withdrawal that
accompanies involuntary withdrawal of MAT during in-
carceration. Our findings are consistent with one past
study that documented the experience of opioid with-
drawal during incarceration [44]. There are two major
implications. First, policies of the criminal justice sys-
tem, including involuntary withdrawal of MAT during
incarceration and re-incarceration for minor parole vio-
lations, may be causing physically painful disruptions in
treatment that dissuade individuals with opioid use disorder
from continuing the most effective forms of treatment. Sec-
ond, for participants who are fearful of developing toler-
ance, opioid-antagonist treatments, such as naltrexone,
may be a better option. As an opioid antagonist, naltrexone
does not cause withdrawal upon cessation, and there is
good evidence that long-acting formulations can reduce
opioid abuse, improve retention in treatment, and may pre-
vent opioid overdose deaths [45-48]. There is also pilot data
supporting the feasibility of using injectable naltrexone in
criminal justice settings in the United States [49]. Our
participants mostly described the traumatic withdrawal
from methadone during incarceration, so the impact of
withdrawal from buprenorphine is still unknown but
warrants additional investigation.
There are other implications of our findings. Interven-
tions should address inmates’ incomplete knowledge about
BMT and facilitate their linkage to MAT prior to relapse.
Participants with negative experiences taking illicit bupre-
norphine (e.g., “it almost killed me”) may have used bupre-
norphine concomitantly with other opioids and therefore
precipitated withdrawal. Buprenorphine education and
proper induction procedures could limit these negative
experiences. A number of participants who were unaware
of buprenorphine at release were eventually able to initiate
BMT following the suggestion of friends, counselors, phy-
sicians, or even parole officers. This suggests that routinely
facilitating entrance into treatment during community re-
entry could prevent relapse (or at least, shorten the time
between relapse and treatment entry). Interventions to
address the adverse re-entry conditions faced by all our
participants, including lack of housing and employmentopportunities, will be more difficult to implement, but
these efforts will also be necessary to prevent relapse
and support successful re-entry.
Our study has limitations. We recruited a convenience
sample from addiction treatment settings, so attitudes of
out-of-treatment former inmates with opioid use dis-
order may not be represented; however, this targeted re-
cruitment allowed us to understand barriers for those who
are ready to stop using opioids and would be amenable to
treatment interventions. Our sample was also mostly
middle-aged former prisoners with long histories of opioid
use disorder, so these findings may not be generalizable to
younger opioid users with less incarceration experience,
who may have different attitudes toward entering opioid
addiction treatment. All interviews were conducted in
New York, which offers Medicaid coverage for BMT, so
access to and knowledge of BMT may be greater than in
other geographic areas. Methadone detoxification upon
incarceration is also readily available in New York City
jails; therefore, the experience of opioid withdrawal upon
incarceration may be worse in other geographic areas.
Finally, because many of the participants were on parole,
they may have been unwilling to fully disclose relapse;
however, we attempted to understand treatment-seeking
decisions, not evaluate the effectiveness of treatment or
the incidence of relapse.
Conclusions
The cycle of incarceration, release, relapse, recidivism, and
re-incarceration has been a problem for individuals with
opioid use disorder for decades. Recently, there have been
efforts to break the cycle by providing enhanced re-entry
services or offering addiction treatment as an alternative
to incarceration. These efforts are important, but may be
insufficient if MAT, including BMT, is not offered as part
of the treatment approach. No one intervention alone will
break the seemingly intractable cycle of incarceration, but
BMTappears to be acceptable, and with targeted interven-
tions, holds great promise for engaging former inmates in
opioid addiction treatment.
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